학술논문
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
Document Type
Artikel
Author
Spelman, T; Herring, WL; Acosta, C; Hyde, R; Jokubaitis, VG; Pucci, E; Lugaresi, A; Laureys, G; Havrdova, EK; Horakova, D; Izquierdo, G; Eichau, S; Ozakbas, S; Alroughani, R; Kalincik, T; Duquette, P; Girard, M; Petersen, T; Patti, F; Csepany, T; Granella, F; Grand'Maison, F; Ferraro, D; Karabudak, R; Sa, MJ; Trojano, M; van Pesch, V; Van Wijmeersch, B; Cartechini, E; Mccombe, P; Gerlach, O; Spitaleri, D; Rozsa, C; Hodgkinson, S; Bergamaschi, R; Gouider, R; Soysal, A; Prevost, J; Garber, J; de Gans, K; Ampapa, R; Simo, M; Sanchez-Menoyo, JL; Iuliano, G; Sas, A; van der Walt, A; John, N; Gray, O; Hughes, S; De Luca, G; Onofrj, M; Buzzard, K; Skibina, O; Terzi, M; Slee, M; Solaro, C; Ramo-Tello, C; Fragoso, Y; Shaygannejad, V; Moore, F; Rajda, C; Morales, EA; Butzkueven, H
Source
Journal of medical economics. 27(1):109-125
Subject
Language
English
English
English
ISSN
1941-837X